Acadia Pharmaceuticals shares rise 4.91% intraday as Teva Pharmaceutical Industries Limited reaffirms earnings guidance for 2025.
ByAinvest
Wednesday, Jul 30, 2025 1:27 pm ET1min read
ACAD--
Acadia Pharmaceuticals Inc. rose 4.91% in intraday trading. The company's stock price increase may be attributed to the positive news from Teva Pharmaceutical Industries Limited, which reported a significant improvement in its second-quarter earnings. Teva's net income for the second quarter was USD 282 million, compared to a net loss of USD 846 million a year ago. This positive financial performance from a competitor in the pharmaceutical industry may have influenced investor sentiment towards Acadia Pharmaceuticals Inc.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet